B. Braun Medical's renal therapies division has announced the availability of the Plasmat Futura System for heparin-induced extracorporeal lipoprotein precipitation (HELP) LDL Apheresis therapy.
HELP therapy is a blood cleansing procedure for the long-term management of patients with severe, congenital lipid disorders that cannot be adequately treated with diet modification or drugs, according to a B. Braun news release.
"The addition of the Plasmat Futura Apheresis system to our existing HELP therapy system exemplifies B. Braun's commitment to providing clinicians with innovative systems that help get their jobs done with more convenience and flexibility," said Samuel Amory, vice president, medical technology division for B. Braun Medical, in the release. "LDL Apheresis therapy is a complex therapy and the Plasmat Futura helps to streamline treatment."
The Plasmat Futura System is aimed at providing an easy-to-use system for clinicians to administer care to patients with severe hypercholesterolemia, according to the release. Features include built-in convenience for maximum mobility and flexibility, as well as an advanced user interface and no requirement for an on-site water treatment system, which are both improvements over the previous HELP system.
Read the news release about the Plasmat Futura System from B. Braun.
More Articles Featuring B. Braun:
B. Braun Receives FDA 510(k) Clearance for New DUPLEX System Use
Aesculap Organizes Laparoscopic Inguinal Hernia Repair Symposia
Webinar Discusses Impact of Regional Anesthesia on Quality, Cost and Patient Satisfaction